Clonally related transformation from Waldenstr öm macroglobulinemia to diffuse large B-cell lymphoma with central nervous system involvement at diagnosis: a case report and literature review
AbstractHistological transformation to diffuse large B-cell lymphoma (DLBCL) rarely occurs in patients with Waldenstr öm macroglobulinemia (WM). The median time from WM diagnosis to DLBCL is 4–5 years. Extranodal involvement is common in transformed WM. However, central nervous system (CNS) involvement is relatively uncommon. Here, we report a case of a simultaneous diagnosis of WM and clonally related DLBCL, w ith the involvement of CNS demonstrated by dual enhancement in MRI. Nevertheless, it is unclear if CNS infiltration is caused by DLBCL or WM for the inaccessibility of brain biopsy. Intensified chemotherapy and ...
Source: Clinical and Experimental Medicine - November 3, 2023 Category: Research Source Type: research
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
AbstractThe ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC) patients with bone metastases (BM). Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were reviewed from60 institutions in 20 countries. Patients were assessed for Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS). Univariate and multivariate analyses were used to explore the association of ...
Source: Clinical and Experimental Medicine - November 2, 2023 Category: Research Source Type: research
Causal relationships between circulating inflammatory cytokines and diffuse large B cell lymphoma: a bidirectional Mendelian randomization study
This study presents evidence supporting a causal relationship between inflammation cytokines and DLBCL. Specifically, MIG/CXCL9 and IP-10/CXCL10 were identified as indicators of upstream causes of DLBCL; while, DLBCL itself was found to elevate the levels of M-CSF, TNF-β, and TRAIL. T hese findings suggest that targeting specific inflammatory factors through regulation and intervention could serve as a potential approach for the treatment and prevention of DLBCL. (Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - November 1, 2023 Category: Research Source Type: research
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study
AbstractImmune checkpoint inhibitors (ICI) are reportedly efficacious against triple-negative breast cancer (TNBC) and are now recommended as first-line therapy. Systemic immunity markers, the absolute lymphocyte count (ALC) and the neutrophil-to-lymphocyte ratio (NLR), have been identified as predict ICI efficacy in patients with various cancers. We retrospectively enrolled 36 TNBC patients who received atezolizumab treatment between September 2019 and May 2021 at eight Japanese medical institutions. We evaluated systemic immunity markers, including dynamic changes in these markers, as predictors of survival benefit deriv...
Source: Clinical and Experimental Medicine - October 30, 2023 Category: Research Source Type: research
Correction to: The effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge: a retrospective follow up study
(Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 30, 2023 Category: Research Source Type: research
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
AbstractSARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19 due to immunosuppression. Anti-SARS-CoV-2 neutralizing antibodies protect against severe COVID-19. This retrospective real-life study aimed to evaluate seropositivity and neutralizing antibody rates against SARS-CoV-2 and its Omicron BA.1 variant in hematological patients. A total of 106 patients with different hematologic malignancies, who have mostly received three or more vaccine doses (73%), were included in this study. Serum was collected between May and...
Source: Clinical and Experimental Medicine - October 28, 2023 Category: Research Source Type: research
Profile of 208 patients with inborn errors of immunity at a tertiary care center in South India
We describe the profile of 208 patients with IEI, a nd to the best of our knowledge, this represents the largest data on IEI from the Indian subcontinent reported so far. (Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 28, 2023 Category: Research Source Type: research
Beh çet’s syndrome: recent advances to aid diagnosis
AbstractBeh çet’s syndrome is a recurring inflammatory multiorgan disorder affecting the skin, mucosa, eyes, joints, stomach, and central nervous system. Behçet’s syndrome epidemiology varies greatly among populations (0.64–420/100,000), and Behçet’s syndrome has gained increasing international accla im in the recent 50 years due to raising awareness of the syndrome, although it is rare in most population. In addition to the unclear etiology of the syndrome, the diagnosis of Behçet’s syndrome is complicated by a vague clinical presentation, phenotypic heterogeneity and/or incomplete represen tation, and the ...
Source: Clinical and Experimental Medicine - October 28, 2023 Category: Research Source Type: research
Clinical advances in immunotherapy for immune-mediated glomerular diseases
ConclusionCertain immunotherapeutic drugs, such as rituximab, belimumab, and eculizumab, have exhibited notable efficacy in treating specific immune-mediated glomerular diseases, thereby providing novel therapeutic approaches for patients. Nonetheless, the efficacy of numerous immunotherapeutic drugs remains to be substantiated. (Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 27, 2023 Category: Research Source Type: research
COX5A as a potential biomarker for disease activity and organ damage in lupus
This study aimed to gain more insights into the underlying immunological pathways and prognostic biomarkers of SLE. Integrated analyses of RNA-seq data from 64 SLE and 62 healthy controls, examining 27 immune cell types to explore the key pathways and driver genes in SLE pathogenesis. Single-cell RNA sequencing data from the skin and kidney were used to determine the association of COX5A expression with organ damage. The associations of COX5A with SLE phenotypes were further evaluated in two independent cohorts, and receiver operating characteristic (ROC) curves were constructed to assess the value of COX5A as a biomarker ...
Source: Clinical and Experimental Medicine - October 27, 2023 Category: Research Source Type: research
Correction to: CXCL6: A potential therapeutic target for inflammation and cancer
(Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 26, 2023 Category: Research Source Type: research
Retraction Note: Long non-coding RNA PICSAR serves as a non-invasive biomarker for the diagnosis and prognosis of cutaneous squamous cell carcinoma
(Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 24, 2023 Category: Research Source Type: research
Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study
In this study, enzyme-linked immunosorbent assays quantified plasma LTBP2 concentrations in 200 individuals (3 5 healthy controls, 42 CTD patients without ILD, 89 CTD-ILD patients, and 34 IPF patients). CTD-ILD and IPF were further classified based on chest imaging pattern and pulmonary function test results. Plasma LTBP2 levels were significantly elevated in the IPF group compared with the CTD-ILD group. RO C analysis further suggested the possible value of LTBP2 in differentially diagnosing CTD-ILD and IPF. Additionally, CTD-ILD patients with progressive lung fibrosis had higher plasma LTBP2 concentrations than those who...
Source: Clinical and Experimental Medicine - October 21, 2023 Category: Research Source Type: research
Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway
In this study, the effect of HSPB6 on osteosarcoma was validated through numerous experiments. HSPB6 was down-regulated in osteosarcoma. As indicated by the result of CCK-8 and colony formation assays, HSPB6 overexpression was likely to inhibit the osteosarcoma cells proliferation, whereas the flow cytometry analysis suggested that apoptosis of osteosarcoma cells was increased after HSPB6 overexpression. Furthermore, transwell and wound healing assays suggested that when HSPB6 was overexpressed, osteosarcoma cells migration and invasion were declined. Moreover, the western blotting assay suggested that the protein level of...
Source: Clinical and Experimental Medicine - October 20, 2023 Category: Research Source Type: research
Retraction Note: The role of fibroblast activation protein in progression and development of osteosarcoma cells
(Source: Clinical and Experimental Medicine)
Source: Clinical and Experimental Medicine - October 17, 2023 Category: Research Source Type: research
